Viatris Inc. (VTRS)

US — Healthcare Sector
Peers: BHC  HLN  OGN  TAK  TEVA  ZTS 

Automate Your Wheel Strategy on VTRS

With Tiblio's Option Bot, you can configure your own wheel strategy including VTRS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol VTRS
  • Rev/Share 12.0338
  • Book/Share 13.2741
  • PB 0.7458
  • Debt/Equity 0.9295
  • CurrentRatio 5.8158
  • ROIC -0.0627

 

  • MktCap 11542134057.0
  • FreeCF/Share 1.585
  • PFCF 6.2081
  • PE -3.3482
  • Debt/Assets 0.3768
  • DivYield 0.0485
  • ROE -0.1992

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation VTRS Goldman -- Neutral -- $10 June 6, 2025

News

ROSEN, NATIONAL TRIAL COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
VTRS
Published: May 11, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / May 11, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Viatris Inc. (NASDAQ: VTRS) between August 8, 2024 and February 26, 2025, both dates inclusive (the "Class Period"), of the important June 3, 2025 lead plaintiff deadline. SO WHAT: If you purchased Viatris securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Read More
image for news ROSEN, NATIONAL TRIAL COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
Viatris Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - VTRS
VTRS
Published: May 11, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 11, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=147969&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Viatris Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - VTRS
Levi & Korsinsky Notifies Shareholders of Viatris Inc.(VTRS) of a Class Action Lawsuit and an Upcoming Deadline
VTRS
Published: May 09, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 9, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=147810&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Levi & Korsinsky Notifies Shareholders of Viatris Inc.(VTRS) of a Class Action Lawsuit and an Upcoming Deadline
VTRS CLASS NOTICE: Viatris Inc. 15% Stock Drop Triggers Securities Class Action -- Contact BFA Law before Court Deadline
VTRS
Published: May 09, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ:VTRS) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/viatris-inc.

Read More
image for news VTRS CLASS NOTICE: Viatris Inc. 15% Stock Drop Triggers Securities Class Action -- Contact BFA Law before Court Deadline
Viatris Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - VTRS
VTRS
Published: May 09, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 9, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=147762&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Viatris Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - VTRS
VTRS DEADLINE REMINDER: Viatris Inc. Investors are Reminded to Contact BFA Law by the June 3 Class Action Deadline (NASDAQ:VTRS)
VTRS
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/viatris-inc.

Read More
image for news VTRS DEADLINE REMINDER: Viatris Inc. Investors are Reminded to Contact BFA Law by the June 3 Class Action Deadline (NASDAQ:VTRS)
Investors in Viatris Inc. Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - VTRS
VTRS
Published: May 09, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 9, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=147699&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Investors in Viatris Inc. Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - VTRS
Viatris Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - VTRS
VTRS
Published: May 09, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 9, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=147694&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Viatris Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - VTRS
VTRS SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Viatris Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
VTRS
Published: May 09, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / May 9, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Viatris Inc. ("Viatris" or "the Company") (NASDAQ:VTRS) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Viatris securities between August 8, 2024 and February 26, 2025, both dates inclusive (the "Class Period").

Read More
image for news VTRS SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Viatris Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Viatris Inc. Class Action: Levi & Korsinsky Reminds Viatris Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - VTRS
VTRS
Published: May 09, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , May 9, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Viatris investors who were adversely affected by alleged securities fraud between August 8, 2024 and February 26, 2025.

Read More
image for news Viatris Inc. Class Action: Levi & Korsinsky Reminds Viatris Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - VTRS
Levi & Korsinsky Reminds Viatris Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - VTRS
VTRS
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 8, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=147661&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Levi & Korsinsky Reminds Viatris Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - VTRS
VIATRIS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Viatris Inc. - VTRS
VTRS
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY AND NEW ORLEANS, LA / ACCESS Newswire / May 8, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 3, 2025 to file lead plaintiff applications in a securities class action lawsuit against Viatris Inc. ("Viatris" or "the Company") (NasdaqGS:VTRS), if they purchased the Company's securities between August 8, 2024 and February 26, 2025, inclusive (the "Class Period").

Read More
image for news VIATRIS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Viatris Inc. - VTRS
Viatris Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - VTRS
VTRS
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 8, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=147596&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Viatris Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - VTRS
Contact Levi & Korsinsky by June 3, 2025 Deadline to Join Class Action Against Viatris Inc.(VTRS)
VTRS
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) of a class action securities lawsuit.

Read More
image for news Contact Levi & Korsinsky by June 3, 2025 Deadline to Join Class Action Against Viatris Inc.(VTRS)
Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains
VTRS
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive

VTRS Q1 earnings and sales beat estimates. Brands business continues to perform well backed by expansion of portfolio.

Read More
image for news Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains
Viatris Q1 Earnings Review: Shares Are Up, Time To Sell (Rating Downgrade)
VTRS
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Positive

Viatris Inc.'s Q1 2025 earnings show declining revenues and profits, yet the stock rose nearly 10% due to stable full-year guidance and positive pipeline updates. The company's significant debt reduction from $22.4bn to $14.3bn came at the cost of selling key assets, raising concerns about long-term growth. Viatris faces challenges like tariffs, FDA warnings, and geopolitical uncertainties, impacting its operational stability and future profitability.

Read More
image for news Viatris Q1 Earnings Review: Shares Are Up, Time To Sell (Rating Downgrade)
Shareholders of Viatris Inc. Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - VTRS
VTRS
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 8, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=147578&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Shareholders of Viatris Inc. Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - VTRS
VIATRIS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Viatris Inc. - VTRS
VTRS
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW ORLEANS, May 08, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 3, 2025 to file lead plaintiff applications in a securities class action lawsuit against Viatris Inc. (“Viatris” or “the Company”) (NasdaqGS: VTRS), if they purchased the Company's securities between August 8, 2024 and February 26, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Pennsylvania.

Read More
image for news VIATRIS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Viatris Inc. - VTRS
Viatris (VTRS) Reports Q1 Earnings: What Key Metrics Have to Say
VTRS
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Neutral

While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Read More
image for news Viatris (VTRS) Reports Q1 Earnings: What Key Metrics Have to Say
Viatris Inc. (VTRS) Q1 2025 Earnings Call Transcript
VTRS
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral

Viatris Inc. (NASDAQ:VTRS ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - CEO Philippe Martin - Chief R&D Officer Doretta Mistras - CFO Corinne Le Goff - Chief Commercial Officer Conference Call Participants Chris Schott - JPMorgan Ashwani Verma - UBS David Amsellem - Piper Sandler Bhavin Patel - Bank of America Umer Raffat - Evercore Operator Good morning, everyone, and welcome to the Viatris Q1 2025 Earnings Call. All participants will be in a listen-only mode.

Read More
image for news Viatris Inc. (VTRS) Q1 2025 Earnings Call Transcript
Viatris (VTRS) Beats Q1 Earnings and Revenue Estimates
VTRS
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive

Viatris (VTRS) came out with quarterly earnings of $0.50 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.67 per share a year ago.

Read More
image for news Viatris (VTRS) Beats Q1 Earnings and Revenue Estimates
Levi & Korsinsky Notifies Viatris Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - VTRS
VTRS
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 8, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=147520&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Levi & Korsinsky Notifies Viatris Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - VTRS
June 3, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VTRS
VTRS
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 8, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=147510&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news June 3, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VTRS
June 3, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VTRS
VTRS
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 8, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=147486&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news June 3, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VTRS
VTRS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Viatris Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
VTRS
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Viatris Inc. ("Viatris" or "the Company") (NASDAQ:VTRS) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Viatris securities between August 8, 2024 and February 26, 2025, both dates inclusive (the "Class Period").

Read More
image for news VTRS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Viatris Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook
VTRS
Published: May 08, 2025 by: PRNewsWire
Sentiment: Neutral

Delivers Total Revenues in Line With Expectations Demonstrating Strength of the Base Business Makes Significant Pipeline Progress With Three Positive Phase 3 Data Readouts Returns More Than $450 Million in Capital to Shareholders Year-to-Date and Reaffirms 2025 Capital Allocation Priorities PITTSBURGH , May 8, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today reported first quarter 2025 financial results and reaffirmed its 2025 outlook[1]. Executive Commentary "2025 is off to a good start as we continue to focus on executing our strategic priorities," said Scott A.

Read More
image for news Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook
Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential
VTRS
Published: May 08, 2025 by: PRNewsWire
Sentiment: Neutral

Treatment With XULANE LO Low Estrogen Dose Achieved Primary and All Secondary Efficacy and Safety Endpoints Results Demonstrated Potential Best-In-Class Patch Performance New Drug Application Submission to U.S. FDA Anticipated in the Second Half of 2025 PITTSBURGH , May 8, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive results of its Phase 3 study (NCT05139121) evaluating the contraceptive efficacy and safety of investigational XULANE LO low dose weekly dermal patch of 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol per day in women of childbearing potential. The study evaluated women of childbearing potential (N=1,272) …

Read More
image for news Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential
Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain
VTRS
Published: May 08, 2025 by: PRNewsWire
Sentiment: Neutral

All Primary and Secondary Endpoints Were Met in Both Phase 3 Studies In Both Acute Pain Models, MR-107A-02 Demonstrated Statistically Significant and Clinically Meaningful Improvement in Pain Compared to Placebo, Significant Reduction in Opioid Usage and Superior Pain Control Versus the Opioid Arm Targeting New Drug Application Submission to U.S. FDA by End of 2025 PITTSBURGH , May 8, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive results from its Phase 3 program of the novel fast-acting formulation of meloxicam (MR-107A-02) for the treatment of moderate-to-severe acute pain. The Phase 3 program consisted of …

Read More
image for news Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Viatris Inc. Lawsuit - VTRS
VTRS
Published: May 08, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , May 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS). Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Read More
image for news The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Viatris Inc. Lawsuit - VTRS
Investors Who Lost Money on Viatris Inc. (VTRS) Should Contact Levi & Korsinsky about Pending Class Action - VTRS
VTRS
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 8, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=147479&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Investors Who Lost Money on Viatris Inc. (VTRS) Should Contact Levi & Korsinsky about Pending Class Action - VTRS

About Viatris Inc. (VTRS)

  • IPO Date 1980-03-17
  • Website https://www.viatris.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Scott Andrew Smith
  • Employees 32000

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.